Bone Biologics CorpNASDAQ BBLG Stock Report

Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is also focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX medical device is a combination product which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The NELL-1/DBX Fusion Device offers a range of procedures including Spine Implants, Non-Union Trauma Cases and Osteoporosis. NELL-1 is a function specific recombinant human protein in laboratory bench models to recapitulate normal human growth and development to provide control over bone and cartilage regeneration. The platform technology is its human protein, known as NELL-1, a skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration.